The use of psychedelic drugs to treat psychiatric disorder is becoming an accepted part of clinical practice. Clinical trials are proceeding and psychedelics have been approved as treatment for some conditions. We know a lot about molecular and synaptic mechanisms and there is a rich and comprehensive body of phenomenological evidence about their effects on conscious experience. However precisely how these mechanistic changes produce these phenomenological effects is still not known. For example how is it the case that a psychedelic experience produced by a serotonin 5-HT2A agonist can alleviate anxiety and distress in a patient with terminal illness? \; Terms like &ldquo\;insight&rdquo\; &ldquo\;reset&rdquo\; \; &ldquo\; ego dissolution&rdquo\; \;which are commonly used to describe or explain results of psychedelic treatment are really placeholders for a full neurocognitive theory with predictive and explanatory power. It remains a possibility that patients&rsquo\; reports do not accurately reflect the underlying causal nature of the phenomenon
As with many psychiatric conditions ethical and political questions psychedelics raise cannot really be resolved absent a comprehensive explanation.
This conference addresses these issues from a variety of perspectives\, clinical\, psychiatric\, neuroscientific and philosophical with contributions from researchers who work at the intersection of these disciplines.
This event will be \;in-person only\, with no virtual elements. \;Registration is necessary as spaces are limited and cannot be guaranteed. If no spaces are available\, you will added to a waitlist and notified if any become available.
Organised in partnership \;by the University of Adelaide \;Department of Philosophy \;and the Monash Centre for Consciousness and Contemplative Studies
Speakers:
\nElizabeth Fisher (Monash University) - \;Increased optimistic engagement with psilocybin: Computational modelling of behaviour in rats
\nDr. Claire Foldi (Monash University) - \;Targeting cognitive function to treat anorexia nervosa: Insights into the effects of psilocybin in animal models
\nDr. Lena Oestreich (The University of Queensland) - \;Microstructural white matter changes in healthy\, psychedelic-naï\;ve humans after subthreshold and fully active doses of psilocybin
\nAssoc Prof Adeel Razi (Monash University) - \;Neural mechanisms of altered states of consciousness under psychedelics
\nProf Philip Gerrans (The University of Adelaide) - \;What exactly dissolves in the experience of ego \;dissolution? \; A neurocognitive account \;
\nDr. Chris Letheby \;(The University of Western Australia) \;- \;How to end the mysticism wars in psychedelic science
\nAss't Prof Ruben Laukkonen - \;The power of insight: Psychedelics and the emergence of new beliefs
\nDr. Paul Liknaitzky (Monash University) - \;Paideiadelic: The conjectured role of acute psychedelic experience in clinical training \;
\nProf Jon Jureidini (The University of Adelaide) - \;Evidence-based or demand-based medicine?
\nAssoc Prof Nin Kurkin \;(The University of Western Australia) \;- \;Psychedelics and environmental virtues
\nDr. Riccardo Miceli \;(The University of Queensland) \;- \;The phenomenology of time and psychedelic-assisted therapy
\nProf Olivia Carter \;(The University of Melbourne) \;- \;Hallucinogen Perceptual Persisting Disorder (HPPD) in the context of psychedelics in psychiatry
\nDr. Raphael Milliere \;(Macquaire University) \;- \;Beyond the unary model of the psychedelic state: The curious case of 5-MeO-DMT
\nProf Susan Rossell \;(Swinburne University) \;- \;TBA
ORGANIZER;CN=Philip Gerrans;CN=Jakob Hohwy;CN=Joseph Melling: METHOD:PUBLISH END:VEVENT END:VCALENDAR